Navigation Links
Seahorse Bioscience, Inc. Appoints In Vitro Technologies Pty Ltd as New Distributor in Australia and New Zealand

NORTH BILLERICA, Mass., March 2, 2011 /PRNewswire/ -- Seahorse Bioscience, Inc., the leader in the design and development of instruments for assessing cellular bioenergetics, has announced In Vitro Technologies Pty Ltd as the new distributor of Seahorse XF Analyzers and consumables in Australia and New Zealand.

Seahorse Extracellular Flux Analyzers provide the first and only kinetic method to measure the two major energy producing pathways - mitochondrial respiration and glycolysis - in living cells in a microplate.

"In Vitro's Life Science product portfolio represents the highest quality laboratory instrumentation, equipment and consumables from around the world. With the interest in cellular bioenergetics in the Australia region the Seahorse brand is a perfect fit in our distribution strategy to focus on in vitro cell research," said Jennifer Parsons, Managing Director of In Vitro Technologies.

Seahorse XF Analyzers enable scientists to assess the impact of drugs, genetic modifications and environment by monitoring the rate that cells consume oxygen and produce metabolic byproducts.

"Our goal was to partner with a distributor who provides quality sales, service and support to customers in the cell based assay market," noted Steve Chomicz, VP Sales and Marketing for Seahorse. "The partnership with In Vitro will allow us to accelerate our sales as they have existing relationships with our ideal customer base."

About In Vitro Technologies Pty Ltd

In Vitro Technologies, founded in 2002, is a privately owned Scientific and Medical distribution company specializing in the sale and support of scientific, clinical diagnostic, medical and related products. The company is owned by JJ Richards & Sons Pty Ltd, one of Australia's largest employers with over 1,200 employees and revenues in excess of $300 million.

For more information, please visit

About Seahorse Bioscience

Seahorse XF instruments have become the new standard in cellular bioenergetic measurements. Scientists worldwide are advancing their research in understanding the role of cellular bioenergetics in Aging, Cancer, Cardiovascular, Cell Physiology, Toxicology & Hepatobiology, Immunology, Infectious Diseases, Mitochondrial Diseases, Model Organisms, Neurodegeneration, Obesity, Diabetes, & Metabolic Disorders, Screening, and Translational Medicine. Seahorse is headquartered in Billerica, Massachusetts US.

For more information, please visit

Contact:  Cynthia Egan, Seahorse Bioscience, Inc., 1-978-671-1600,

SOURCE Seahorse Bioscience, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Related biology technology :

1. Seahorse Bioscience, Inc. Acquires BioProcessors Corp.
2. New Cellular Bioenergetics Workshops Series Inaugurated by Seahorse Bioscience with Two of the Worlds Leading Bioenergetics Researchers
3. Seahorse Bioscience to Present Novel Cellular Bioenergetics Data in Collaboration with University of Nebraska at AACR Metabolism and Cancer Conference
4. TheScientist Awards Seahorse XF96 Analyzer a Top Ten Innovation for 2009
5. Seahorse Bioscience to Present at 2010 UBS Global Life Sciences Conference
6. Anthera Pharmaceuticals Completes $19 Million Financing; Appoints Christopher S. Henney as Chairman
7. Omeros Appoints David A. Mann to its Board of Directors
8. RainDance Technologies Appoints Olex Vice President, System Development
9. ARCA biopharma Appoints William R. Hiatt as Director of Clinical and Regulatory Strategy
10. WuXi AppTec Appoints Garry Takle, Ph.D. as VP of Operations and Joseph Hughes, Ph.D. as VP of Testing Services for Philadelphia Facility
11. Medizone International, Inc. Appoints Dr. Michael E. Shannon to Its Board of Directors
Post Your Comments:
(Date:6/23/2016)... /PRNewswire/ - FACIT has announced the creation of ... company, Propellon Therapeutics Inc. ("Propellon" or "the Company"), ... portfolio of first-in-class WDR5 inhibitors for the treatment ... represent an exciting class of therapies, possessing the ... cancer patients. Substantial advances have been achieved with ...
(Date:6/23/2016)... 2016  The Biodesign Challenge (BDC), a university competition ... harness living systems and biotechnology, announced its winning teams ... New York City . The ... projects at MoMA,s Celeste Bartos Theater during the daylong ... senior curator of architecture and design, and Suzanne ...
(Date:6/23/2016)... Ky. , June 23, 2016 ... two Phase 1 clinical trials of its complement ... placebo-controlled, single and multiple ascending dose studies designed ... pharmacodynamics (PD) of subcutaneous injection in healthy adult ... subcutaneously (SC) either as a single dose (ranging ...
(Date:6/23/2016)... ... June 23, 2016 , ... Regulatory Compliance Associates® Inc. (RCA), ... free webinar on Performing Quality Investigations: Getting to Root Cause. ... no charge. , Incomplete investigations are still a major concern to the Regulatory ...
Breaking Biology Technology:
(Date:5/12/2016)... 12, 2016 , a brand ... overview results from the Q1 wave of its quarterly ... was consumers, receptivity to a program where they would ... health insurance company. "We were surprised to ... Michael LaColla , CEO of Troubadour Research, "primarily ...
(Date:4/28/2016)... India , April 28, 2016 ... Infosys (NYSE: INFY ), and Samsung SDS, a ... that will provide end customers with a more secure, ... services.      (Logo: ) , ... services, but it also plays a fundamental part in enabling ...
(Date:4/26/2016)... Research and Markets has announced ... 2016-2020"  report to their offering.  , ,     (Logo: ... analysts forecast the global multimodal biometrics market to ... period 2016-2020.  Multimodal biometrics is being ... the healthcare, BFSI, transportation, automotive, and government for ...
Breaking Biology News(10 mins):